CVKD (Cadrenal Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on CVKD (Cadrenal Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

CVKD

Cadrenal Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 10, 2025
Cadrenal Therapeutics, Inc.
Nov 8, 2025
CVKD: Acquires Factor XIa Inhibitors…
Sep 30, 2025
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Sep 29, 2025
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Sep 15, 2025
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin…
May 19, 2025
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
Apr 3, 2025
CVKD: Preparing for Phase 3 Trial of Tecarfarin…
Mar 31, 2025
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
Mar 13, 2025
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial…
Mar 7, 2025
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Mar 4, 2025

Reviews